APECED: JAK Inhibition in an Adult Case with Long-Term Follow-up

December 2025 in “ Journal of Human Immunity ”

Edwin Pardo-Díaz, Juliana Lores

We don't know much about this study yet.

We're maintaining the world's largest resposity of hair loss research. You can help out the community by sending a PDF of this study here . Not sure how to get a study's PDF? You can email the authors of the study.

View this study on rupress.org →

Discuss this study in the Community →

Related Community Posts Join

6 / 1000+ results

community Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting

in Chat 28 upvotes 5 days ago

PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.

community Kintor KX -826 Pyrilutamide Adds 1 Year Phase 3 Trial For Safety

in Technology 57 upvotes 2 years ago

KX-826/pyrilutamide is undergoing an additional one-year safety and efficacy trial in China after a six-month study. Some participants speculate on the reasons for the extended trial and discuss the potential of other treatments.

community KX-826 Phase II Results Just Dropped (Male AGA) – Key Takeaways

in Research/Science 16 upvotes 8 months ago

KX-826 Phase II results show that a 0.5% concentration performs better than 1% for treating male pattern baldness. Concerns about receptor upregulation from long-term DHT antagonism were mentioned.

community Alopecia Areata Question

in Treatment 2 upvotes 5 years ago

A user with alopecia totalis, borderline universalis, seeks advice on getting into a Xeljanz trial or appealing insurance for coverage. They experienced significant hair regrowth but are now seeing hair loss again and want to try Xeljanz.

community Kintor Pharma Announces Completion of First Patient Enrollment in KX-826 Long-term Safety Phase III Trial for Treatment of AGA

in Research/Science 11 upvotes 2 years ago

Kintor Pharma has finished enrolling the first patient in a Phase III trial for KX-826, a treatment for androgenetic alopecia (AGA). One user has set a reminder to check back on the topic in a year.

community EMA is re-examining Winlevi (clascoterone at lower concentration)

in Treatment 8 upvotes 9 months ago

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.